133 related articles for article (PubMed ID: 25905694)
1. Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.
Di Pompo G; Salerno M; Rotili D; Valente S; Zwergel C; Avnet S; Lattanzi G; Baldini N; Mai A
J Med Chem; 2015 May; 58(9):4073-9. PubMed ID: 25905694
[TBL] [Abstract][Full Text] [Related]
2. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
4. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
5. Novel cinnamyl hydroxyamides and 2-aminoanilides as histone deacetylase inhibitors: apoptotic induction and cytodifferentiation activity.
Valente S; Tardugno M; Conte M; Cirilli R; Perrone A; Ragno R; Simeoni S; Tramontano A; Massa S; Nebbioso A; Miceli M; Franci G; Brosch G; Altucci L; Mai A
ChemMedChem; 2011 Apr; 6(4):698-712. PubMed ID: 21374822
[TBL] [Abstract][Full Text] [Related]
6. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models.
Liu S; Cheng H; Kwan W; Lubieniecka JM; Nielsen TO
Mol Cancer Ther; 2008 Jun; 7(6):1751-61. PubMed ID: 18566246
[TBL] [Abstract][Full Text] [Related]
8. The design, synthesis and structure-activity relationships of novel isoindoline-based histone deacetylase inhibitors.
Shultz M; Fan J; Chen C; Cho YS; Davis N; Bickford S; Buteau K; Cao X; Holmqvist M; Hsu M; Jiang L; Liu G; Lu Q; Patel C; Suresh JR; Selvaraj M; Urban L; Wang P; Yan-Neale Y; Whitehead L; Zhang H; Zhou L; Atadja P
Bioorg Med Chem Lett; 2011 Aug; 21(16):4909-12. PubMed ID: 21742496
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors suppress the growth of human osteosarcomas in vitro and in vivo.
Wu Z; Ma C; Shan Z; Ju Y; Li S; Zhao Q
J BUON; 2013; 18(4):1032-7. PubMed ID: 24344034
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression.
Salvador MA; Wicinski J; Cabaud O; Toiron Y; Finetti P; Josselin E; Lelièvre H; Kraus-Berthier L; Depil S; Bertucci F; Collette Y; Birnbaum D; Charafe-Jauffret E; Ginestier C
Clin Cancer Res; 2013 Dec; 19(23):6520-31. PubMed ID: 24141629
[TBL] [Abstract][Full Text] [Related]
11. Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities.
Zhang Y; Feng J; Jia Y; Wang X; Zhang L; Liu C; Fang H; Xu W
J Med Chem; 2011 Apr; 54(8):2823-38. PubMed ID: 21476600
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
Picarda G; Lamoureux F; Geffroy L; Delepine P; Montier T; Laud K; Tirode F; Delattre O; Heymann D; Rédini F
Clin Cancer Res; 2010 Apr; 16(8):2363-74. PubMed ID: 20371692
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor vorinostat suppresses the growth of uterine sarcomas in vitro and in vivo.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Petru E; Zatloukal K; Denk H
Mol Cancer; 2010 Mar; 9():49. PubMed ID: 20202195
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells.
Yang C; Choy E; Hornicek FJ; Wood KB; Schwab JH; Liu X; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2011 Feb; 67(2):439-46. PubMed ID: 20461381
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDA-MB231 breast cancer cells.
Librizzi M; Longo A; Chiarelli R; Amin J; Spencer J; Luparello C
Chem Res Toxicol; 2012 Nov; 25(11):2608-16. PubMed ID: 23094795
[TBL] [Abstract][Full Text] [Related]
17. New aryldithiolethione derivatives as potent histone deacetylase inhibitors.
Tazzari V; Cappelletti G; Casagrande M; Perrino E; Renzi L; Del Soldato P; Sparatore A
Bioorg Med Chem; 2010 Jun; 18(12):4187-94. PubMed ID: 20576572
[TBL] [Abstract][Full Text] [Related]
18. Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.
Bennani-Baiti IM; Machado I; Llombart-Bosch A; Kovar H
Hum Pathol; 2012 Aug; 43(8):1300-7. PubMed ID: 22245111
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.
Grisendi G; Spano C; D'souza N; Rasini V; Veronesi E; Prapa M; Petrachi T; Piccinno S; Rossignoli F; Burns JS; Fiorcari S; Granchi D; Baldini N; Horwitz EM; Guarneri V; Conte P; Paolucci P; Dominici M
Stem Cells; 2015 Mar; 33(3):859-69. PubMed ID: 25420617
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors.
Zhu Y; Chen X; Wu Z; Zheng Y; Chen Y; Tang W; Lu T
Arch Pharm Res; 2012 Oct; 35(10):1723-32. PubMed ID: 23139122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
